1)      Lv, L. #;Maimaitiming, M. #; Huang, Y. #; Yang, J.; Chen, S.; Sun, Y.; Zhang, X.; Li, X.;Xue, C.; Wang, P.*; Wang, C.*;Liu, Z.*Discovery of quinazolin-4(3H)-one derivatives as novel AChE inhibitors with anti-inflammatory activities,European Journal of Medicinal Chemistry,2023,254:115346.

2)      Li, R.#; Zhou, Y.#; Zhang, X.; Yang, L.; Liu, J.; Wightman, S. M.; Lv, L.; Liu, Z.*; Wang, C.*; Zhao, C*. Identification of Marine Natural Product Pretrichodermamide B as a STAT3 Inhibitor for Efficient Anticancer Therapy. Mar. Life Sci. Technol., 2023,5, 94-101.

3)      Maimaitiming M. #;Lv L.#; Zhang X.; Xia S.; Li X.; Wang P.*;Liu Z.*; Wang C-Y*. Semi-Synthesis and Biological Evaluation of 25(R)-26-Acetoxy-3β,5α-Dihydroxycholest-6-One. Marine Drugs. 2023; 21(3):191.

4)      Li, H.#; Ouyang, S.#; Zhang, Y.; Peng, K.; Fang, W.; Liu, Z.*; Wang, C.*; Zhang, X.*; Wang, Y.* Structural Optimization of Imidazo[1, 2-a]pyridine Derivatives for theTreatment of Gastric Cancer via STAT3 Signaling Pathway. Eur. J. Med. Chem., 2022, 244:114858.

5)      Li, H.#; Maimaitiming, M.#; Zhou, Y.; Li, H.; Wang, P.; Liu, Y.; Schaberle, T. F.; Liu, Z.*; Wang, C.* Discovery of Marine Natural Products as Promising Antibiotics against Pseudomonas aeruginosa. Mar. Drugs, 2022, 20, 192.  

6)      Liu, Z.#; Li, Y.#; Chen, H.; Lai, H. T.; Wang, P.; Wu, S. Y.; Wold, E. A.; Leonard, P. G.; Joseph, S.; Hu, H.; Chiang, C. M.; Brasier, A. R.*; Tian, B.*; Zhou, J.* Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site. J. Med. Chem.,2022, 65,3, 2388-2408.   

7)      Liu, Z.*, Wang, P., Wold, E.A., Song, Q., Zhao, C., Wang, C.* and Zhou, J.* Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer. J. Med. Chem.,2021, 64 (8), 4257-4288.

8)      Liu, Z.; Chen, H.; Wang, P.; Li, Y.; Wold, E. A.; Leonard, P. G.; Joseph, S.; Brasier, A. R.; Tian, B.; Zhou, J. Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation. J. Med. Chem., 2020, 63, 5242-5256.

9)      Niu, Q.#; Liu, Z.#; Alamer, E.; Fan, X.; Chen, H.; Endsley, J.; Gelman, B. B.; Tian, B.; Kim, J. H.; Michael, N. L.; Robb, M. L.; Ananworanich, J.; Zhou, J.; Hu, H. Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV. J. Clin. Invest. 2019, 129, 3361-3373. (#co-first author)

10)   Liu, Z.; Tian, B.; Chen, H.; Wang, P.; Brasier, A. R.; Zhou, J. Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation. Eur. J. Med. Chem. 2018, 151, 450-461.

11)   Tian, B.#; Liu, Z.#; Yang, J.; Sun, H.; Zhao, Y.; Wakamiya, M.; Chen, H.; Rytting, E.; Zhou, J.; Brasier, A. R. Selective Antagonists of the Bronchiolar Epithelial NF-κB-Bromodomain-Containing Protein 4 Pathway in Viral-Induced Airway Inflammation. Cell Rep. 2018, 23, 1138-1151. (#co-first author)

12)  Ali, S. R.#; Liu, Z.#; Nenov, M. N.; Folorunso, O.; Singh, A.; Scala, F.; Chen, H.; James, T. F.; Alshammari, M.; Panova-Elektronova, N. I.; White, M. A.; Zhou, J.; Laezza, F. Functional Modulation of Voltage-Gated Sodium Channels by a FGF14-Based Peptidomimetic. ACS Chem. Neurosci. 2018, 9, 976-987. (#co-first author)

13)  Liu, Z.; Wang, P.; Chen, H.; Wold, E. A.; Tian, B.; Brasier, A. R.; Zhou, J. Drug Discovery Targeting Bromodomain-Containing Protein 4. J. Med. Chem. 2017, 60, 4533-4558.

14)  Liu, Z.; Wild, C.; Ding, Y.; Ye, N.; Chen, H.; Wold, E. A.; Zhou, J. BH4 domain of Bcl-2 as a novel target for cancer therapy. Drug Discov. Today 2016, 21, 989-996.

15)  Liu, Z.; Ding, Y.; Ye, N.; Wild, C.; Chen, H.; Zhou, J. Direct Activation of Bax Protein for Cancer Therapy. Med. Res. Rev. 2016, 36, 313-341.

16)  Liu, Z.; Yue, X.; Song, Z.; Peng, X.; Guo, J.; Ji, Y.; Cheng, Z.; Ding, J.; Ai, J.; Geng, M.; Zhang, A. Design, synthesis and pharmacological evaluation of 2-(thiazol-2-amino)-4-arylaminopyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors. Eur. J. Med. Chem. 2014, 86, 438-448.

17)  Liu, Z.; Ai, J.; Peng, X.; Song, Z.; Wu, K.; Zhang, J.; Yao, Q.; Chen, Y.; Ji, Y.; Yang, Y.; Geng, M.; Zhang, A. Novel 2,4-Diarylanninopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities. ACS Med. Chem. Lett. 2014, 5, 304-308.